A computational study shows the promising activity of bioactive compounds in pomegranate as inhibitors of SARS-CoV-2 duplication.
The sudden appearance of COVID-19 has not only led the health authorities to take quick action in this regard, but also to seek quick solutions from the scientific community.
Recent studies have found an important enzyme of SARS-CoV-2 that plays a key role in the duplication of virus particles, making it a drug discovery target.
A collaborative study among investigators from Egypt, China, and India revealed that some bioactive compounds in pomegranate could be theoretically used to treat the outbreak of COVID-19.
This computational study of the interaction between the enzyme and the compounds, displayed that three of them may serve as potential anti-COVID-19 lead molecules for further optimization and drug development to control the disease.
Pedunculagin, tercatain, and punicalin were found to faithfully interact with the enzyme, showing their successfully inhibition of the virus duplication.